RAPT Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• RAPT Therapeutics Inc RAPT.OQ reported a quarterly adjusted loss of 65 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-5.68. The mean expectation of five analysts for the quarter was for a loss of 64 cents per share. Wall Street expected results to range from -72 cents to -49 cents per share.

• Reported revenue was zero​; analysts expected zero.

• RAPT Therapeutics Inc's reported EPS for the quarter was a loss of 65 cents​.

• The company reported a quarterly loss of $17.64 million.

• RAPT Therapeutics Inc shares had risen by 24.9% this quarter and lost 21.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 42.6% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for RAPT Therapeutics Inc is $27.00, about 63% above its last closing price of $9.99

This summary was machine generated from LSEG data August 7 at 05:23 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)